Cellular reprogramming of somatic cells to patient-specific induced pluripotent stem cells (iPSCs) enables in vitro modelling of human genetic disorders for pathogenic investigations and therapeutic screens 1-7 . However, using iPSC-derived cardiomyocytes (iPSC-CMs) to model an adult-onset heart disease remains challenging owing to the uncertainty regarding the ability of relatively immature iPSC-CMs to fully recapitulate adult disease phenotypes. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited heart disease characterized by pathological fatty infiltration and cardiomyocyte loss predominantly in the right ventricle 8 , which is associated with life-threatening ventricular arrhythmias. Over 50% of affected individuals have desmosome gene mutations, most commonly in PKP2, encoding plakophilin-2 (ref. 9). The median age at presentation of ARVD/C is 26 years 8 . We used previously published methods 1,10 to generate iPSC lines from fibroblasts of two patients with ARVD/C and PKP2 mutations 11, 12 . Mutant PKP2 iPSC-CMs demonstrate abnormal plakoglobin nuclear translocation and decreased b-catenin activity 13 in cardiogenic conditions; yet, these abnormal features are insufficient to reproduce the pathological phenotypes of ARVD/C in standard cardiogenic conditions. Here we show that induction of adult-like metabolic energetics from an embryonic/glycolytic state and abnormal peroxisome proliferator-activated receptor gamma (PPAR-c) activation underlie the pathogenesis of ARVD/C. By co-activating normal PPAR-alpha-dependent metabolism and abnormal PPAR-c pathway in beating embryoid bodies (EBs) with defined media, we established an efficient ARVD/C in vitro model within 2 months. This model manifests exaggerated lipogenesis and apoptosis in mutant PKP2 iPSC-CMs. iPSC-CMs with a homozygous PKP2 mutation also had calcium-handling deficits. Our study is the first to demonstrate that induction of adult-like metabolism has a critical role in establishing an adult-onset disease model using patient-specific iPSCs. Using this model, we revealed crucial pathogenic insights that metabolic derangement in adult-like metabolic milieu underlies ARVD/C pathologies, enabling us to propose novel disease-modifying therapeutic strategies.
clinically feasible therapy. These limiting factors impose significant constraints in developing therapies for human ARVD/C.
Using four retroviral vectors containing Oct4, Sox2, Klf4 and cMyc, we first generated several iPSC lines from fibroblasts of a patient with clinical ARVD/C and a homozygous c.2484C.T mutation in PKP2 that causes cryptic splicing with a 7-nucleotide deletion in exon 12, leading to frame-shift of the carboxy-terminal amino acids 11 . Three iPSC lines were extensively characterized: JK#2, JK#7 and JK#11 ( Fig. 1 and Supplementary Figs 1 and 2 ). All iPSC clones expressed pluripotent markers, including Oct4, Tra1-81, Nanog and SSEA4, had normal karyotypes, and formed teratoma when injected into severe combined immunodeficient (SCID) mice. Pluripotent status of mutant PKP2-iPSCs was also demonstrated by the methylation patterns of Nanog promoter regions ( Fig. 1c ) in comparison to parental mutant PKP2 fibroblasts and H9 human embryonic stem cells (hESCs). Global transcriptome expression profiles showed that all mutant PKP2-iPSC lines showed a higher degree of similarity with H9 hESCs and normal iPSCs (CF-iPSCs, female, characterized in Supplementary Fig. 3 ) than their parental fibroblasts ( Fig. 1f ). Importantly, all three JK mutant iPSC lines showed silenced exogenous retroviral transgenes and activation of endogenous pluripotent genes ( Supplementary Fig. 2 ). Genomic DNA sequencing and messenger RNA analysis confirmed the homozygous c.2484C.T mutation in PKP2 that caused predominantly cryptic splicing in exon 12 of three JK lines ( Supplementary Figs 1d  and 2b) . These results demonstrated the successful reprogramming of parental mutant PKP2 fibroblasts to iPSC lines.
We differentiated human H9 hESCs, CF-iPSCs and mutant PKP2-iPSCs to beating EBs (Supplementary Videos 1 and 2) using a standard cardiogenic protocol 14 . Consistent with previous findings in ARVD/C cell line and mouse models with desmoplakin downregulation/deletion 13 , we observed abnormal nuclear translocation of junction plakoglobin proteins (PKG) ( Fig. 2a, b ), and very low b-catenin activity and expression in mutant iPSC-CMs ( Supplementary Fig. 4 ) but not in normal hESC-CMs under baseline cardiogenic conditions. These results indicate that mutant PKP2 proteins with frame-shifted C-terminals fail to anchor PKG to the sarcolemmal membrane, resulting in PKG nuclear translocation and downregulation of b-catenin activities 13 . However, no exaggerated lipogenesis (by Nile Red staining) or apoptosis (by TdT-mediated dUTP nick end labelling (TUNEL) assay) in H9 hESC-or mutant iPSC-CMs was found after culturing for 2-3 months in this baseline cardiogenic condition ( Fig. 2c) , an observation that is consistent with the delayed, adult-onset clinical course of ARVD/C.
We then focused our studies on the cardiomyocyte portions (positive for cardiac a-actinin or troponin I (CTNI)) of beating EBs. We counted (1) the percentage of cardiomyocytes that possessed positive TUNEL nuclear staining as the cardiomyocyte (CM) apoptotic index, and (2) the percentage of cardiomyocytes that contained any Nile-Red-positive lipid droplets as the indicator of lipogenesis in cardiomyocytes. The baseline apoptotic index and percentages of lipid-laden cardiomyocytes are 1.8 6 0.3 and 0.8 6 0.5% for 60-day-old hESC-CMs, and 2.1 6 0.6 and 0.9 6 0.1% for 60-day-old mutant PKP2 iPSC-CMs (no statistical difference between these two groups), respectively. Because the major metabolic differences between embryonic and adult cardiomyocytes are (1) embryonic cardiomyocytes use mostly glycolysis for energy production, and (2) adult cardiomyocytes produce most energy via fatty acid oxidation (FAO) but retain capacity to readily switch to glucose or other substrate utilization when fatty acid is not available or FAO is compromised 15, 16 , we first created a lipogenic milieu in beating EBs with an adipogenic cocktail (insulin, dexamethasone and 3-isobutyl-1-methilxanthine (IBMX), termed the 3-factor (3F) protocol) [17] [18] [19] in an attempt to induce adult-like energy metabolism and accelerate pathogenesis in mutant iPSC-CMs. With this 3F protocol, we observed mildly increased lipogenesis with minimal apoptosis after 4-5 weeks of treatment (13.2 6 4.3 and 4.8 6 1.0% lipid-laden cardiomyocytes and 6.3 6 1.4 and 3.9 6 1.8% apoptotic cardiomyocytes in hESC-CMs and mutant PKP2 iPSC-CMs, respectively, P 5 non-significant between groups, Fig. 2d-k) . Notably, this 3F protocol induced more expression of PPAR-alpha (PPAR-a), the major transcriptional regulator of fatty acid metabolism in adult cardiomyocytes 16 , in beating mutant iPSC-EBs than in hESC-EBs ( Fig. 2g ). PPAR-c, which should be minimally activated in normal cardiomyocytes, was slightly activated by this 3F protocol in both beating EBs. Because PPAR-c pathway has been reported to be abnormally hyperactivated in right ventricle tissue samples of ARVD/C hearts 20 and transgene-induced overexpression of PPAR-c in mouse cardiomyocytes leads to dilated cardiomyopathy 21 , we added 5 mM rosiglitazone 22 and 200 mM indomethacin 23 to the 3F protocol to further induce abnormal PPAR-c over-activation in beating EBs (termed the 5-factor (5F) protocol). After 4-5 weeks of treatment with 5F, mutant iPSC-CMs demonstrated exaggerated lipogenesis (31.6 6 3.3% versus 13.5 6 3.5% in hESC-CMs, P , 0.05) and pronounced apoptosis (39.6 6 8.5% versus 5.4 6 0.9% in hESC-CMs, P , 0.05, Fig. 2h-k) . Quantitative real-time PCR with reverse transcription (qRT-PCR) analysis also confirmed the higher expression of adipogenic PPAR-c/aP2 (fatty acid-binding protein, also known as FABP4) genes and downregulation of the pro-survival Bcl2 gene in beating mutant PKP2-EBs when compared to normal hESC-EBs or CF-iPSC-EBs ( Fig. 2g and Supplementary Fig. 5a , b). Results of cardiomyocytes apoptosis and lipogenesis in beating EBs after control, 3F or 5F treatment are summarized in Fig. 2j , k. We also observed abnormal PPAR-c nuclear staining in mutant PKP2 iPSC-CMs after 2 weeks of 5F treatment ( Supplementary Fig. 5c ), indicating that abnormal PPAR-c activation may have a significant role in mediating mutant iPSC-CM pathology. We previously showed that we could use cardiac alphamyosin heavy chain promoter-driven puromycin resistance (a-MHC-Puro r ) to efficiently isolate cardiomyocytes (.95% purity) from beating EBs 14 . We therefore generated mutant iPSC lines (JK#2 and JK#11) with a-MHC-Puro r to enable purification of cardiomyocytes for further testing. In comparison to puromycin-isolated hESC-CMs, purified mutant iPSC-CMs showed higher PPAR-c activation, lower BCL2 mRNA levels, and higher apoptotic caspase 3 expressions after 5F treatment (Supplementary Fig. 5d ). More importantly, rosiglitazone and indomethacin alone without the other three factors induced PPAR-c activation only but did not induce exaggerated lipogenesis or apoptosis ( Supplementary  Fig. 5e -g), indicating that activation of both normal PPAR-a and abnormal PPAR-c pathways in mutant PKP2 iPSC-CMs is required for eliciting pathologies of ARVD/C. We further verified that the pathogenic specificity of these ARVD/C phenotypes is due to the PKP2 mutation in mutant iPSC-EBs by introducing the wild-type (WT) PKP2 gene back into mutant iPSC-CMs, containing a-MHC-Puro r , with a lentiviral transduction method ( Fig. 3a ). After transducing beating mutant iPSC-EBs with WT PKP2 (verified by the expression of tagged green fluorescent protein, GFP), abnormal PKG nuclear localization ( Fig. 3b ), apoptosis ( Fig. 3c ) and lipogenesis ( Fig. 3d ) in puromycin-purified mutant iPSC-CMs were corrected by the expression of WT PKP2 (GFP 1 ), but not in isolated CMs without WT-PKP2-GFP after the 5F protocol. We measured the number of lipid droplets in each cardiomyocyte as the degree of lipogenesis in Fig. 3d because cardiomyocytes containing WT-PKP2-GFP still had few tiny lipid droplets remaining after 5F treatment ( Fig. 3d , left image). Also, control GFP vector alone without WT-PKP2 did not correct the PKG nuclear translocation (Fig. 3b ) or the large number of big lipid droplets found in mutant PKP2 iPSC-CMs ( Fig. 3d , right image) after pathogenic induction. These findings support that observed pathological phenotypes are the result of mutated PKP2 genes in iPSCs.
Among the components of pathogenic 5F protocol, insulin, dexamethasone and IBMX simulate natural hormonal regulation of cardiomyocyte metabolism, but rosiglitazone and indomethacin are not natural human ligands. Therefore, we searched for a natural ligand that could replace rosiglitazone and indomethacin for inducing abnormal PPAR-c activation. We found that the endogenous PPAR-c activator 13-hydroxyocta-decadienoic acid (13-HODE, a major component of the oxidized low-density lipoprotein (oxLDL)) 22 could replace rosiglitazone and indomethacin in the 5F protocol for abnormal PPAR-c 
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activation, leading to extensive lipogenesis (37.5 6 6.0%) and apoptosis (22.4 6 4.0%) in mutant iPSC-CMs ( Fig. 3e ). Moreover, to support the crucial pathogenic role of coactivation of abnormal PPAR-c and normal PPAR-a pathways in ARVD/C, we showed that blockade of PPAR-c overactivation with PPAR-c antagonists, GW9662 (GW) 22 or T0070907 (T007) 23 , during pathogenic induction with media containing 13-HODE and 3-factors, prevents apoptosis and lipogenesis in mutant iPSC-CMs ( Fig. 3f-h) . Also, blockade of PPAR-a activation with an antagonist, 2 mM GW6471, after 5F treatment (Supplementary Fig. 6 ) or activation of PPAR-c alone ( Supplementary Fig. 5e -g) did not induce significant ARVD/C pathologies, supporting the crucial role of PPAR-a/PPAR-c coactivation in ARVD/C pathogenesis. Significant FAO and b-oxidation activated by PPAR-a seem to be required for cardiomyocyte apoptosis as well ( Supplementary Fig.  6b-e ). Furthermore, because mitochondrial function is tightly linked to energy metabolism and apoptosis 24 , we decreased reactive oxygen species (ROS) production from mitochondria with ROS scavengers, 1 mM N-acetyl-cysteine or ascorbic acid individually, in the 5F pathogenic protocol, which markedly decreased cardiomyocyte death in mutant PKP2-beating EBs (Fig. 3i, j) . Using a Seahorse XF96 Extracellular Flux Analyzer 25 , functional assays of FAO and glycolysis in live cells showed that mutant PKP2 iPSC-CMs and normal iPSC-CMs derived from a second normal iPSC line (hS-iPSC, male, characterized in Supplementary Fig. 7 ) had dominant glycolytic energetics (an embryonic pattern 15 ) at the baseline ( Fig. 4 and Supplementary Fig. 8 ). After activation of PPAR-a by 3F, mutant and normal iPSC-CMs had similar levels of glycolysis but significant activation of FAO (an adult-like pattern) when compared to the non-induced, baseline conditions (zero factor). Compared to 3F induction, mutant PKP2 iPSC-CMs after pathogenic coactivation of PPAR-a and PPAR-c by 5F demonstrated overall depressed energy metabolism with 86% reduction in FAO and 74% reduction in glycolysis, resulting in a fuel shift from using both fatty acids and glucose to dominant glucose utilization (including glycolysis and pyruvate oxidation), much like the so-called metabolic burnt-out state observed in failing hearts 26 (Fig. 4 ). This fuel-shift after pathogenic induction is accompanied by significant downregulation of mRNA transcripts of carnitine palmitoyltransferase-1B (CPT1B) and pyruvate dehydrogenase kinase-4 (PDK4), leading to inhibition of FAO and activation of pyruvate dehydrogenase (PDH) for increased pyruvate oxidation 16, 26 , respectively ( Fig. 4i-k) . Thus, results from immunocytochemical, genetic and metabolic assays support strongly that coactivation of PPAR-a and PPAR-c by hormones and small molecules accelerates the pathogenesis and establishes an efficient in vitro model of ARVD/C, recapitulating the metabolic and pathological signatures of failing ARVD/C hearts within 2 months.
We also used an episomal method 10 to generate three lines of genomeintegration free iPSC (SW#5, SW#6 and SW#7) from a second patient with clinical ARVD/C ( Supplementary Fig. 9 ) and a heterozygous c.2013delC in exon 10 of PKP2 (termed delC PKP2 mutation) that causes frame-shift and premature termination in exon 10. Confirmation of pluripotent status and the heterozygous c.2013delC in PKP2 of these three SW iPSC clones are shown in Supplementary Figs 10 and 11 . Prematurely-terminated delC mutant PKP2 transcripts are probably unstable and degraded to undetectable levels (see Supplementary Figs  10b, c and 11h ). SW iPSC-CMs also showed increased nuclear PKG translocation ( Supplementary Fig. 12a-c) and very low b-catenin nuclear localization ( Supplementary Fig. 4) as described for the homozygous c.2484C.T mutant PKP2 iPSC-CMs. We induced ARVD phenotypes from SW#5 and SW#7 mutant iPSC-CMs but not in normal female 
LETTER RESEARCH
CF-iPSC-CMs with the 5F protocol. Only the 5F protocol induced coactivation of normal PPAR-a and abnormal PPAR-c pathways that led to exaggerated lipogenesis and cardiomyocyte apoptosis in delC PKP2 iPSC-CMs ( Supplementary Fig. 12 ), consistent with the results shown in Fig. 2 . The second hS-iPSC line was also used to show that the 5F protocol did not induce exaggerated lipogenesis or cardiomyocyte apoptosis in normal male iPSC-CMs ( Supplementary Fig. 7f ). We further used JK mutant iPSC-CMs to investigate other cardiomyocyte properties that may contribute to pathogenesis. Compared to H9 hESC-CMs in baseline conditions, mutant iPSC-CMs demonstrated slower intracellular calcium ([Ca 21 ] i ) relaxation after pacing only in high extracellular Ca 21 media (5.8 mM) with a prolonged relaxation time constant, but not in normal Ca 21 media (1.8 mM). However, after 5F pathogenic induction, mutant iPSC-CMs demonstrated a prolonged [Ca 21 ] i relaxation phase even in normal Ca 21 media after pacing ( Supplementary Fig. 13a-d) , indicating abnormal [Ca 21 ] i handling capability. Furthermore, using puromycin-purified cardiomyocytes and compared to hESC-CMs, qRT-PCR analysis of mutant iPSC-CMs in baseline conditions showed mildly decreased mRNA expression levels of sarcoplasmic reticulum Ca 21 -ATPase (SERCA, for Ca 21 re-uptake) with preserved Na 1 /Ca 21 exchanger 1 (NCX1, for [Ca 21 ] i extrusion) expression, which may explain the impaired [Ca 21 ] i relaxation of mutant iPSC-CMs only in high extracellular Ca 21 media at baseline. In contrast, after 5F treatment, both NCX1 and SERCA expression levels were significantly downregulated ( Supplementary Fig. 13e, f) relative to hESC-CMs, which would account for the further impaired [Ca 21 ] i relaxation phase of mutant iPSC-CMs even in normal Ca 21 media. Also, electrophysiological a, Diagram of lentiviral vectors used to stably integrate control-GFP or WT-PKP2-GFP into mutant iPSC-CMs. b, Top panels, PKG (red) remained restricted to nuclei with control-GFP vectors; bottom panels, PKG distributed at both cell membrane and nucleus (Hoechst) with WT-PKP2-GFP of purified mutant iPSC-CMs. c, After 5F and WT PKP2-GFP lentiviral infection, TUNEL nuclear staining could only be found in GFP-negative CMs. d, Large number of lipid droplets (red) could only be found in WT PKP2-GFP-negative (left, 22.5 6 3.8) or control-GFP-positive CMs (right, 30.3 6 12.2 lipid droplets per CM), but not in WT PKP2-GFP-positive CMs (5.5 6 2.0 small lipid droplets per CM). e, 13-HODE (20 mg ml 21 ) with 3F could replace 5F for pathogenic induction. f, 3 mM GW and 0.5 mM T007 (not shown) prevent pathogenic induction by 13-HODE13F. g, h, Summary of CM apoptotic index (g) and degrees of lipogenesis (h) in mutant PKP2-CMs. The percentage of CMs that have TUNEL staining and lipid droplets in mutant iPSC-CMs after treatment with 3F, 13-HODE13F, 13-HODE13F1GW, 13-HODE13F1T007 and 5F (re-plot from Fig. 2j , k) are: 3.9 6 1.8 and 4.8 6 1.0%, 22.4 6 4.0 and 37.5 6 6.0%, 2.5 6 2.0 and 3.9 6 2.5%, 1.5 6 0.9 and 4.0 6 1.0% and 39.6 6 8.5 and 31.6 6 3.3%, respectively. i, N-acetyl-cysteine (NAC) prevented CM apoptosis induced by 5F. j, The apoptotic index for mutant iPSC-CMs after 5F with 1 mM NAC or ascorbic acid (AA) is 11.4 6 2.3% and 3.8 6 1.2%, respectively (versus 2.1 6 0.6% in control and 39.6 6 8.5 after 5F). The number in each column represents the number of biological replicates tested. Asterisks indicate P , 0.05 and NS, no significant difference by ANOVA.
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properties of JK PKP2 mutant iPSC-CMs are different from H9 hESC-CMs ( Supplementary Fig. 14) at baseline and show further impairment after PPAR-a and PPAR-c coactivation. Future mechanistic studies are needed to determine the roles of impaired [Ca 21 ] i handling and altered electrical properties in mediating pathologies or arrhythmia of mutant iPSC-CMs 8, 27 .
Finally, to explain the predominant pathology in the right ventricle of ARVD/C hearts, we increased the number of Islet l-positive (Isl1 1 ) cardiac progenitor cells by approximately fourfold in JK#2 and JK#11 mutant PKP2 iPSCs with 1 mM 6-bromoindirubin-39-oxime (BIO) 28 to simulate natural right ventricle formation from Isl1 1 progenitor cells of the secondary heart field 29 (Supplementary Fig. 15a-c) . We also used 100 ng ml 21 Dickkopf-1 (Dkk1) 28 to decrease the number of Isl1 1 progenitor cells and, subsequently, right-ventricle-like cardiomyocytes. After 5F pathogenic induction, EBs with enriched Isl1 1 cells had significantly more lipogenesis and apoptosis in cardiomyocytes than EBs with minimal numbers of Isl1 1 progenitor cells ( Supplementary Fig. 15d-g) . This result supports the notion that Isl1 1 cells confer the dominant pathologies in the right ventricle 30 .
In conclusion, using patient-specific mutant PKP2-iPSCs and various pathogenic conditions, we accelerate the pathogenesis of an adult-onset disease. We demonstrate the importance of PPAR-a/PPAR-c coactivation, ROS production, fatty acid oxidation and Isl1 1 cells in the pathogenesis of ARVD/C. These efficient in vitro iPSC models recapitulate the pathognomonic features of ARVD/C and enable pathogenic investigation and therapeutic screens.
METHODS SUMMARY
The retroviral and episomal methods of generating iPSCs from normal and patients' fibroblasts were performed as published previously 1, 10 . Human ESC and iPSC culture methods, lentiviral transduction and derivation of cardiomyocytes using standard cardiogenic protocols were described previously 14 . ARVD/C fibroblasts were obtained from Johns Hopkins University and normal fibroblasts from UCSD with approved protocols at each institution. Genetic sequencing and Combining data shown in a-h, these results support that both normal and mutant iPSC-CMs have embryonic metabolism at the baseline, and show significantly increased FAO after 3F with ability to switch between FAO and glucose utilization (an adult-like metabolic pattern). Mutant iPSC-CMs after 5F behave like failing cardiomyocytes (also see Supplementary Fig. 8 ) with pathological glucose-dominant metabolism. i, A simple diagram to illustrate substrate utilization pathways in cardiomyocytes. j, k, qRT-PCR analysis of puromycin-purified mutant iPSC-CMs showed that mutant iPSC-CMs displayed significantly decreased expression of CPT1B (j) and PDK4 (k) mRNA transcripts when compared to control H9 hESC-CMs after 5F induction, leading to enhanced pyruvate oxidation and decreased FAO, respectively. Please see Supplementary Information for detailed legend of Fig. 4 . Single asterisk indicates P , 0.05 and NS, no significant difference by ANOVA. P values are shown when unpaired t-test was performed.
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Illumina microarray data were performed at the Sanford-Burnham Medical Research Institute (SBMRI) core facility and Scripps Research Institute. Karyotyping was performed by Cell Line Genetics. Standard techniques were used for immunostaining, cryosections, qRT-PCR, TUNEL assay, teratoma formation/ section, and Ca 21 imaging with Fura-2 AM dyes. Immunostaining sections were analysed with SlideBook software for lipid and TUNEL counts. Data were analysed with the StatView/JMP program (SAS Institute) and presented as mean 6 s.e.m.
[Ca 21 ] i relaxation curve fitting was performed with SigmaPlot 8.0 software using the Marquardt-Levenberg algorithm to achieve the best fit. Statistical difference was analysed by an ANOVA procedure for multiple comparisons and by the unpaired t-test for pair-wise comparisons with a P-value , 0.05 considered statistically significant.
